Core Viewpoint - The legal opinion letter from Grandall Law Firm (Xi'an) confirms that Shaanxi Srey New Materials Co., Ltd. has obtained the necessary approvals and authorizations for its 2023 stock option incentive plan adjustments, ensuring compliance with relevant laws and regulations [1][5][9] Group 1: Legal Framework and Compliance - The law firm was appointed as a special legal advisor for the 2023 stock option incentive plan of Shaanxi Srey New Materials Co., Ltd. [1] - The legal opinion is based on various laws including the Company Law, Securities Law, and relevant regulations from the Shanghai Stock Exchange [1][4] - The firm confirms that the company provided all necessary and accurate documentation for the legal opinion [4][5] Group 2: Approval and Authorization - The adjustments to the stock option incentive plan have received necessary approvals from the board and supervisory committee [6][7] - The company has publicly disclosed the list of incentive recipients and received no objections during the public notice period [6][7] - The board approved the adjustment of the exercise price for the stock options to 9.70 yuan per share [9] Group 3: Specific Adjustments - The adjustments to the stock option plan were made in response to the company's cash dividend distribution, which amounted to 29.17 million yuan [8] - The exercise price was adjusted from 9.74 yuan to 9.70 yuan per share following the dividend distribution [9] - The adjustments comply with the provisions of the incentive plan and relevant regulations [9]

Core Viewpoint - The legal opinion letter outlines the approval and authorization process for the 2024 stock option incentive plan of Shenzhen Haon Automotive Electronics Equipment Co., Ltd, including the granting of reserved stock options, adjustment of exercise prices, and cancellation of unexercised stock options due to unmet performance conditions [1][6][11]. Group 1: Approval and Authorization - The company held its third board meeting on July 11, 2024, where it approved the stock option incentive plan and related proposals [3]. - The third supervisory board meeting on the same day also approved the incentive plan and confirmed the eligibility of the incentive objects [3]. - The company announced the list of incentive objects on July 13, 2024, confirming their compliance with relevant laws and regulations [3]. - The third extraordinary general meeting of shareholders on July 29, 2024, authorized the board to implement the incentive plan [3]. - On August 2, 2024, the board approved the initial grant of 3.581 million stock options to 200 incentive objects at an exercise price of 53.99 yuan per option [3][5]. Group 2: Reserved Stock Options - The reserved stock options will be granted on July 7, 2025, to 33 incentive objects, totaling 419,000 options at an exercise price of 53.49 yuan per option [4][6]. - The granting of reserved stock options is in accordance with the approved incentive plan and management regulations [6][8]. Group 3: Adjustment of Exercise Price - The exercise price for the stock options has been adjusted to 53.49 yuan per option due to the company's profit distribution plan [10]. - The adjustment complies with the provisions of the incentive plan and relevant regulations [10][11]. Group 4: Cancellation of Stock Options - The board approved the cancellation of 243,000 stock options held by 12 incentive objects who left the company for personal reasons [5]. - Additionally, 317,300 stock options were canceled due to the failure to meet performance conditions for the first exercise period [11]. - The cancellation of stock options aligns with the provisions of the incentive plan and management regulations [11].

Core Viewpoint - The company has announced an adjustment to the exercise price of stock options under its 2024 stock option incentive plan, setting the new exercise price at 53.49 yuan per share [1][6][7]. Group 1: Approval Procedures - The company held meetings on July 7, 2025, where the board and supervisory committee approved the adjustment of the exercise price for the stock options [1]. - The relevant proposals regarding the stock option incentive plan were reviewed and approved, including the management measures for the implementation of the plan [1][3]. - The supervisory committee did not receive any objections during the public notice period [2]. Group 2: Adjustment of Exercise Price - The adjustment of the exercise price is due to the company's dividend distribution, which necessitates a recalibration of the exercise price according to the established formula [6]. - The new exercise price of 53.49 yuan per share reflects the adjustments made following the dividend distribution [1][6]. Group 3: Impact on the Company - The adjustment of the exercise price will not have a substantial impact on the company's financial status or operational results, nor will it harm the interests of the company and its shareholders [6][7]. - The board's remuneration and assessment committee has reviewed the adjustment and confirmed its compliance with relevant regulations [6][7]. Group 4: Legal Opinions - The legal opinion provided by a law firm confirms that the adjustment of the exercise price complies with the relevant regulations and the company's articles of association [7].

Core Viewpoint - The company has conducted its 13th meeting of the third supervisory board, where several key resolutions regarding the 2024 stock option incentive plan were approved, including the cancellation of certain stock options and adjustments to the exercise price [1][2][3]. Group 1: Supervisory Board Meeting - The meeting was held on June 30, 2025, with all three supervisors present, and was conducted in accordance with relevant laws and regulations [1]. - The resolutions passed included the cancellation of stock options due to unmet exercise conditions, which aligns with legal requirements and does not harm the interests of the company or its shareholders [1][2]. Group 2: Stock Option Incentive Plan Adjustments - The supervisory board approved adjustments to the exercise price of the stock options, confirming that these changes comply with the relevant regulations and do not negatively impact shareholder interests [2]. - A total of 419,000 stock options will be granted to 33 eligible incentive objects on July 7, 2025, with an exercise price set at 53.49 yuan per option [3]. Group 3: Use of Idle Funds - The board agreed to continue using up to 200 million yuan of idle raised funds for cash management, which is expected to enhance the preservation and appreciation of the company's cash without adversely affecting its operations [3][4].

Group 1 - The company held its fourth supervisory board meeting on July 7, 2025, with all three supervisors present, confirming the legality and validity of the meeting procedures [1] - The supervisory board approved the proposal regarding the lifting of the first lock-up period for the 2024 restricted stock incentive plan, as the performance indicators for the release conditions have been met, allowing for the release of 0.25% of the total share capital for eligible incentive objects [2][3] - The supervisory board also agreed to the repurchase and cancellation of restricted stocks that were granted to departing incentive objects but have not yet been released, confirming compliance with relevant laws and regulations [2][3]

杭州解百集团股份有限公司监事会 二〇二五年七月七日 杭州解百集团股份有限公司 第十一届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 鉴于 1 名激励对象因主动辞职与公司终止劳动关系，根据《激励计划》相关规 定，公司监事会同意回购注销前述 1 名激励对象已获授但尚未解除限售的限制性股 票合计 27,000 股。另外，因公司 2023 年度和 2024 年度权益分派方案已实施完毕， 根据《上市公司股权激励管理办法》《杭州解百集团股份有限公司 2021 年限制性股 票激励计划》等相关规定，公司监事会同意将回购价格调整至 2.559 元/股。 表决结果：同意 5 票，反对 0 票，弃权 0 票，表决通过。 特此公告。 杭州解百集团股份有限公司（以下简称"公司"）于 2025 年 7 月 7 日以现场会 议方式在杭州市环城北路 208 号坤和中心 37 楼会议室召开了第十一届监事会第十三 次会议。本次会议通知于 2025 年 6 月 19 日以通讯方式送达各位监事，会议应参加 监事 5 人，实际参加监 ...

Core Viewpoint - The chairman of New Mileage, Lin Yanglin, is under investigation by the Taiyuan Municipal Xiaodian District Supervisory Committee, which has led to his inability to perform his duties. The company stated that the matter is unrelated to its operations and has not been asked to assist in the investigation [1]. Group 1: Company Operations - New Mileage's main business segments include medical services and traditional Chinese medicine, with medical services accounting for approximately 80% of its revenue [2]. - In 2024, New Mileage reported a revenue of 3.799 billion yuan and a net profit attributable to shareholders of 115 million yuan [1]. - The company operates six regional medical centers across various provinces and has a total of 24 hospitals, including three tertiary hospitals and 14 secondary or higher-level hospitals [2]. Group 2: Corporate Structure and History - New Mileage's pharmaceutical business is primarily centered around the "Duyiwei" brand of traditional Chinese medicine, which contributes about 20% to its revenue [4]. - The company was formerly known as Hengkang Medical and became controlled by Beijing New Mileage Health Industry Group in 2022 [4]. - New Mileage Group manages over 40 hospitals across nearly 20 provinces, with a total bed capacity of 30,000, ranking among the top three in the country [4]. Group 3: Financial and Regulatory Issues - On June 20, Lin Yanglin and the CFO Liu Jun were subjected to regulatory discussions by the Gansu Securities Regulatory Bureau due to non-compliance with accounting standards related to stock incentive plans and construction project accounting [6]. - The financial discrepancies have led to inaccurate disclosures in the consolidated balance sheets for the fiscal years 2023 and the first three quarters of 2024, violating the regulations on information disclosure for listed companies [6].

Group 1: Management Changes in the Alcohol Industry - The alcohol industry has seen a series of high-level management changes since last year, with companies like Yanghe, China Resources Beer, and Jinzhongzi Wine experiencing shifts in leadership, indicating a strong intent from shareholders and investors to boost performance [1] - Jinzhongzi Wine's General Manager He Xiuxia has resigned, and the company is facing significant market share pressure, with 2024 revenue projected to drop to 925 million yuan, a stark contrast to over 2 billion yuan in previous cycles [5] - Yanghe has appointed Gu Yu as the new Party Secretary, replacing Zhang Liandong, who has stepped down amid a challenging period for the white liquor industry [6][7] Group 2: Trade and Regulatory Developments - The Ministry of Commerce has concluded an anti-dumping investigation into EU brandy, determining that dumping margins range from 27.7% to 34.9%, leading to the imposition of anti-dumping duties starting July 5, 2025 [2][3] - A total of 34 EU brandy exporters, including well-known brands like Martell and Hennessy, can avoid these duties by adhering to price commitments approved by Chinese authorities [3] Group 3: Market Trends and Promotions - Taobao Flash Sale has initiated a new subsidy program, investing 50 billion yuan, resulting in a significant increase in orders, particularly in the alcohol sector, with some brands seeing order volumes double [4] - Kuaizi Jiao reported that its high-end "Jian" series products have not performed as expected, with sales and consumer feedback being less favorable compared to older products [10] - Xijiu has launched a promotional campaign offering buy-three-get-one-free deals on various products, indicating a strategy to boost sales through consumer incentives [11]

Core Viewpoint - The announcement details the completion of the initial registration for the 2025 Restricted Stock Incentive Plan by Shanghai NAR Industrial Co., Ltd, highlighting the approval processes, stock allocation, and performance assessment criteria for the incentive plan [1][2][3]. Summary by Sections Approval Process - The 2025 Restricted Stock Incentive Plan has undergone necessary approval procedures, including the review and consent from the Compensation and Assessment Committee of the Board [1][2]. - No objections were raised during the public notice period by the Supervisory Board [1]. Initial Grant of Restricted Stock - A total of 91.706 million shares were granted to 37 core personnel, representing 19.74% of the incentive plan and 0.27% of the total share capital on the announcement date [2][3]. - The effective period of the incentive plan is up to 48 months from the date of the initial grant [2]. Lock-up Period and Release Schedule - The lock-up periods for the granted restricted stocks are set at 12, 24, and 36 months, with specific release percentages of 35% for the first two periods and 30% for the last [3][4]. Performance Assessment Criteria - The performance assessment for the incentive plan will be based on the company's total revenue and net profit for the fiscal years 2025-2027, with specific targets set for each assessment year [5][6]. - The performance targets are equally weighted, with a 50% contribution from both revenue and profit metrics [6]. Financial Impact and Fund Utilization - The funds raised from the stock grants will be used to supplement the company's working capital [8]. - The issuance of restricted stocks will have an impact on the company's financial status, with specific amortization costs outlined for the years 2025 to 2028 [8][9]. Stock Structure Changes - Following the completion of the grant registration, the total number of shares increased to 341,535,127, with no change in the control of the company or its compliance with listing conditions [7][8].

截至2025年7月4日收盘，天臣医疗（688013）报收于29.99元，较上周的27.31元上涨9.81%。本周，天 臣医疗7月4日盘中最高价报31.96元，股价触及近一年最高点。6月30日盘中最低价报27.47元。天臣医疗 当前最新总市值24.34亿元，在医疗器械板块市值排名115/126，在两市A股市值排名4712/5149。 公司于2025年7月3日完成2023年限制性股票激励计划第二个归属期的股份登记工作。本次归属股票数量 为556,000股，来源于公司从二级市场回购的A股普通股股票，归属人数为89人。公司实际收到89名激励 对象缴纳的资本总额共计人民币5,977,000.00元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 天臣国际医疗科技股份有限公司于2023年12月27日开始实施股份回购计划，回购资金总额逐步调整为不 低于4600万元，不超过8000万元，回购期限延长至2025年12月26日。截至2025年6月30日，公司已累计 回购股份2505324股，占公司总股本的3.09%，支付的资金总额约为4249.89万 ...